AMGN · News · 20260910N
Guidance and Outlook
AMGEN INC · 2026-09-10 · Importance 51 · Surprise 60 · No source text
Third-party reporting states that Amgen raised its full-year 2026 revenue and earnings-per-share guidance. The increase reflects management’s greater confidence after a second-quarter growth rebound and double-digit sales growth from 22 products. The reports do not provide the revised dollar ranges or quantify the expected revenue impact from Tezspire and Repatha acceleration.
Key facts
- Amgen is anticipated to report an EPS increase of 0.89% and revenue growth of 3.68% in its upcoming earnings report (analyst expectations). source
- AMGN raised full-year 2026 revenue and EPS guidance. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | +0.6% | Amgen is anticipated to report an EPS increase of 0.89% and revenue growth of 3.68% in its upcoming earnings report (analyst expectations). |
| net_income | positive | contingent | — | Amgen is anticipated to report an EPS increase of 0.89% and revenue growth of 3.68% in its upcoming earnings report (analyst expectations). |
| revenue | positive | probable | — | AMGN raised full-year 2026 revenue and EPS guidance. |
| net_income | positive | probable | — | AMGN raised full-year 2026 revenue and EPS guidance. |